Keywords: Amtagvi; Braftovi; Cotellic; Keytruda; Mekinist; Mektovi; Opdivo; Opdualag; Tafinlar; Yervoy; Zelboraf; adverse effects; aldesleukin; binimetinib; cobimetinib; cyclophosphamide; dabrafenib; dosage; drug interactions; efficacy; encorafenib; fludarabine; ipilimumab; lifileucel; melanoma; nivolumab; pembrolizumab; relatlimib; safety; trametinib; vemurafenib.